Introduction {#sec0005}
============

Nutritional support is one of the most important issues in the management of patients who undergo hematopoietic stem cell transplantation (HSCT).[@bib0200], [@bib0205] Many factors induce changes in the metabolism during HSCT[@bib0210] including high-dose chemotherapy and total body irradiation, mucositis with painful ulcers, diminished ingestion, nausea, vomiting and diarrhea.[@bib0205] Allogeneic HSCT (allo-HSCT) usually produces the greatest changes in body composition and muscle metabolism, infections and acute graft-versus-host disease (aGVHD).[@bib0215], [@bib0220]

Malnutrition has been identified as a major challenge in HSCT. Furthermore in malnourished (under and overweight) patients, studies have shown a higher risk of complications: changes in the body composition resulting in electrolyte imbalance and impairment of the immune system (both associated with longer engraftment time) and most of all, higher non-relapse mortality rates in the immediate post-transplant period.[@bib0225], [@bib0230], [@bib0235], [@bib0240]

Energy requirements after transplantation usually increase by 30--50%, which is why nutritional support has been suggested as a contributing factor to an improved engraftment time and lower risk of infection during the neutropenic stage.[@bib0240], [@bib0245], [@bib0250] Parenteral nutrition is supportive care, which maintains the nutritional status of patients during the transplant process.

There are now many nutritional parameters available in the nutritional assessments of cancer patients and specifically HSCT patients. This paper presents the impact of pre-HSCT and post-HSCT biochemical and anthropometric evaluations on the clinical outcomes of HSCT. Thus, the aim of this study was to identify any associations between several nutritional parameters and the incidence of gastrointestinal and hepatic aGVHD, infectious complications, length of hospital stay, delayed neutrophil or platelet engraftment and overall survival (OS).

Methods {#sec0010}
=======

Patients {#sec0015}
--------

All patients who underwent autologous HSCT (auto-HSCT) and allo-HSCT between 2011 and 2014 at the Pontificia Universidad Católica de Chile were included in this study. Data were collected from the electronic and paper charts as well as the HSCT program database. The study was approved by the institutional review board.

Transplant procedure {#sec0020}
--------------------

After the decision to transplant had been made, patients underwent a number of evaluations to determine their suitability for transplantation and, when apt, auto-HSCT or allo-HSCT was performed. Conditioning regimens for the HSCT are shown in [Table 1](#tbl0005){ref-type="table"}.

In sibling and matched unrelated HSCT, prophylaxis for graft-versus-host disease (GVHD) was made with cyclosporine and methotrexate or tacrolimus and methotrexate. In cord blood HSCT, GVHD prophylaxis was made with cyclosporine and mycophenolate mofetil.

Prophylaxis against infectious diseases for all the patients included levofloxacin (500 mg q.d.) starting on Day −1 until neutrophil recovery or febrile neutropenia, acyclovir (400 mg t.i.d) starting on Day −1 until Day +365, fluconazole (200 mg q.d.) starting on Day −1 until Day +100 and sulfamethoxazole trimethoprim (q.d. 3 times a week) starting with neutrophil recovery until Day +365. Similarly, all patients were kept in isolated rooms with high efficiency particulate air filters and positive pressure during the neutropenic phase of the transplant. Patients were given a neutropenic diet and received intravenous filgrastim 300 μg starting on Day +5 until neutrophil engraftment.

Nutritional evaluation {#sec0025}
----------------------

A nutritional evaluation was conducted at the time of HSCT, ten days after HSCT and before patient discharge. Pre-transplant assessments included body mass index (BMI), anthropometry, and measurements of the albumin, prealbumin and total urinary nitrogen (TUN) levels. Clinical and laboratory variables including cell counts, hematological condition and conditioning regimens were recorded.

Post-transplant assessment included BMI, albumin, prealbumin, TUN and type of nutritional support \[oral, oral plus supplement, enteral nutrition or total parenteral nutrition (TPN)\].

Grip strength was measured using a Jamar analogue hand dynamometer with participants seated in the upright position, their elbow by their side and flexed at right angles, with neutral wrist position. The best of three grip strength tests was calculated. This measurement was extrapolated to theoretical 85 percentile tables by gender and age.

Definitions {#sec0030}
-----------

BMI was calculated according to Hannan.[@bib0255] BMI \< 20 kg/m^2^ was considered underweight, between 20--25 kg/m^2^ normal, 25--30 kg/m^2^ overweight and \>30 kg/m^2^ obese. Prealbumin was quantified using the nephelometry method with normal values between 18 and 38 mg/dL, albumin was quantified using the colorimetric method with normal values between 3.5 and 5.0 mg/dL and 24-h TUN was assessed using the Kjeldahl method. Patients who required TPN were prescribed for a specific number of days. Mucositis (Grade 1 to 4) and infectious complications (Grade 1 to 5) were graded according to the National Health Institute and Common Terminology Criteria for Adverse Events v 4.03.[@bib0260] Acute GVHD (hepatic and intestinal) was graded according to the International Bone Marrow Transplant Registry (IBMTR) scale.[@bib0265] Time to neutrophil and platelet engraftment was defined according to standard definitions: neutrophil count \>500 cells/μL for three consecutive days and platelet count \>50,000 cells/μL for seven consecutive days without the patient requiring transfusions.

Statistical analysis {#sec0035}
--------------------

Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) software (Version 20; Chicago, IL, USA). Results are presented as mean values. The ANOVA test was used to compare three mean values of the evaluations performed before the transplant, ten days after transplant and at discharge and the *t*-test to compare two means (auto-HSCT vs. allo-HSCT). Multivariate analysis used the Spearman coefficient. BMI, dynamometry, albumin, prealbumin, TUN, triglycerides, time to platelet and neutrophil engraftment, length of hospital stay and OS were considered continuous variables and the need of TPN, aGVHD and presence of mucositis, categorical variables. The Cox Proportional Hazards test was used to estimate the OS.[@bib0270] OS and non-relapse mortality were analyzed by the Kaplan--Meier method. Statistical significance was set for *p*-values \<0.05.

Results {#sec0040}
=======

Characteristics of patients and the hematopoietic stem cell transplantation procedure {#sec0045}
-------------------------------------------------------------------------------------

Fifty patients transplanted between 2011 and 2014 were analyzed. Patient characteristics are shown in [Table 1](#tbl0005){ref-type="table"}. Thirty-three (66%) were men and seventeen (34%) were women. The average age was 41 years (range: 17--67 years). In all, 32 allo-HSCT and 18 auto-HSCT were performed. Indications for HSCT were acute leukemias in 26 patients (52%), multiple myeloma in 13 (26%), lymphoma in seven (14%), severe aplastic anemia in three (6%) and myelodysplastic syndrome in one (2%). The average length of hospital stay was 32 days (range: 19--109 days).

Conditioning regimens ([Table 2](#tbl0010){ref-type="table"}) were myeloablative in 42 cases (84%) and reduced intensity in eight cases (16%). The median follow-up time was 41 months (range: 2--83 years).

Nutritional status before and after hematopoietic stem cell transplantation {#sec0050}
---------------------------------------------------------------------------

At admission for HSCT, there were no significant differences regarding nutritional parameters between the groups of allo-HSCT and auto-HSCT patients ([Table 3](#tbl0015){ref-type="table"}). After transplantation only the triglycerides levels were significantly higher in the allo-HSCT Group compared to auto-HSCT Group. The other parameters were similar between both groups ([Table 3](#tbl0015){ref-type="table"}).

On combining the HSCT groups, there were significant reductions in the BMI, and prealbumin and albumin levels in the post-transplant period compared to the pre-transplant period. Triglyceride levels were significantly higher in the post-transplant assessment. No differences in TUN and dynamometry were found between the three evaluations ([Table 4](#tbl0020){ref-type="table"}).

Considering the type of HSCT, albumin levels decreased significantly in both the allo-HSCT and auto-HSCT Groups after transplantation. However, the reduction in prealbumin, as well as the increase in triglyceride levels, were only significant in the allo-HSCT group, while a significant drop in BMI was only seen in the auto-HSCT group ([Table 5](#tbl0025){ref-type="table"}).

Post-transplant complications {#sec0055}
-----------------------------

Considering all patients, 37 (74%) developed mucositis \[allo-HSCT: *n* = 24 (75%) and auto-HSCT: *n* = 13 (72%); *p*-value \<0.05\]. According to the degree of mucositis three patients had Grade 1, 15 patients Grade 2, 18 patients Grade 3 and one had Grade 4 ([Figure 1](#fig0005){ref-type="fig"}). Of the 37 patients with mucositis, 27 (73%) required TPN \[allo-HSCT: *n* = 22 (81%) and auto-HSCT: *n* = 5 (19%)\] and 10 (27%) some other kind of nutritional support. According to the type of transplant, 28% (5/18) of auto-HSCT and 69% (22/32) of allo-HSCT patients required TPN. [Figure 2](#fig0010){ref-type="fig"} shows the distribution of nutritional support in the different groups. Eight patients without mucositis also required TPN because of severe nausea and vomiting.

Considering the 32 allo-HSCT patients, nine (28%) developed intestinal aGVHD (five patients submitted to unrelated HSCT and four to related HSCT) and 23 (72%) did not develop intestinal aGVHD. The severity was Grade II-IV in five (56%) and Grade III-IV in four (44%). The average time from HSCT to aGVHD was 34 days (range: 16--80 days). Overall, 69% (22/32) of the allo-HSCT patients required TPN. All of the patients who developed intestinal aGVHD required TPN and 57% (13/23) of the patients without intestinal GVHD required TPN, mainly due to anorexia.

The 41-month OS was 79% (auto-HSCT: 81%; allo-HSCT: 75%; *p*-value = NS). The non-relapse mortality rate (2 auto-HSCT and 4 allo-HSCT) was 12% at 41 months (11% auto-HSCT and 13% allo-HSCT; *p*-value = NS).

Multivariate analysis {#sec0060}
---------------------

In the multivariate analysis, none of the pre-HSCT nutritional parameters was associated with transplant outcomes. However, several post-HSCT nutritional parameters were statistically associated with transplant outcomes. Specifically, ten days after transplant, albumin was associated with length of hospital stay and time to platelet engraftment; TUN was correlated with time to platelet engraftment and days of TPN with length of hospital stay, time to neutrophil engraftment and time to platelet engraftment. Only TUN was associated with time to neutrophil engraftment in the pre-discharge evaluation. Finally, OS was not affected by any variable in the multivariate analysis ([Table 6](#tbl0030){ref-type="table"}).

Discussion {#sec0065}
==========

This is the first study from Chile to report on nutritional support in HSCT patients. Nutritional impairment is significant after transplantation[@bib0275] and is associated with worse outcomes.[@bib0280] Malnourishment increases the risk of death, mucositis, aGVHD and infectious complications in patients submitted to HSCT.[@bib0240], [@bib0280], [@bib0285]

Several studies have addressed the topic of specific nutritional parameters in HSCT, with discordant findings. Schulte et al., without demonstrating any association between BMI and transplant complications, reported a significant decrease in BMI after HSCT, which reverted one year after transplantation.[@bib0245] Other authors have identified low pre-transplant BMI as an independent risk factor for mortality.[@bib0290], [@bib0295], [@bib0300], [@bib0305] Urbain et al. showed that aGVHD and anorexia during transplant were associated with significant reductions in BMI in an allo-HSCT cohort.[@bib0240] This study found an overall drop in BMI after HSCT, with statistical significance only for the auto-HSCT Group.

When considering other parameters, the study of Schulte et al. showed a significant reduction in prealbumin levels at Day +14 and +28 after HSCT.[@bib0245] In the current study, this reduction was noticed even before, at Day +10, and persisted until patient discharge. Albumin levels showed a significant reduction in the same period irrespective of the type of HSCT, which correlated with both a longer length of hospital stay and platelet engraftment time.

The differences found between allo-HSCT and auto-HSCT may suggest a higher degree of catabolism in the allo-HSCT setting. Specifically, this study observed that earlier in the course of HSCT, the TUN levels tend to be higher after auto-HSCT compared to allo-HSCT. However, before discharge TUN was higher, albeit not significantly, in the allo-HSCT Group than the auto-HSCT Group. Moreover, albumin levels can change in acute renal failure and during the use of transfusion support, which is very common in this kind of patient.[@bib0310], [@bib0315] A study of Underzo et al.[@bib0320] showed that after TPN, albumin levels after HSCT did not change over one week but prealbumin levels did, which makes this variable a more accurate parameter for diet and nutritional assessments. Together with prealbumin, research has shown decreases of other parameters after HSCT such as transferrin and retinol binding protein that might predict malnutrition in allo-HSCT and auto-HSCT.[@bib0325] In this study, higher TUN levels were associated with slower neutrophil and platelet engraftment. This may suggest that higher TUN levels are a surrogate of more severe infectious complications, which could be associated to delayed engraftment time. Research failed to show an association between nutritional support and time to neutrophil engraftment.[@bib0330], [@bib0335] However, a study by Habjibabaie et al. suggested that BMI, but not TUN, was inversely correlated with the neutrophil engraftment time.[@bib0340]

When considering complications after HSCT, the incidence of mucositis reported in this study was 74%, similar to the incidence of 70% reported in the literature.[@bib0345] Days of TPN correlated with the length of hospital stay and time to platelet and neutrophil engraftment.

None of the nutritional factors analyzed at different time points including BMI, albumin, prealbumin, TUN and TPN, were associated with OS in this study, and survival rates were similar between allo-HSCT and auto-HSCT patients, possibly due to the early nutritional support provided to all patients and the small number of patients analyzed which precluded statistically significant differences. The high mortality rate in auto-HSCT patients is possibly associated with the low number of this type of patients included in this study.

This research was unable to demonstrate any association between TPN and a higher rate of intestinal aGVHD. However, there are possible explanations for the association between mucositis, aGVHD and TPN that have been suggested before. Mucosa-associated lymphoid tissue (MALT), while normally acting as an immunological barrier, may suffer severe damage during conditioning for HSCT. The subsequent bacterial and toxin translocation may act as a potent inflammatory stimulus for the development of acute aGVHD.[@bib0350], [@bib0355] As shown by Mattsson et al., the oral feeding route seems to have a protective role against the development of GVHD.[@bib0360] In their study of 231 patients submitted to myeloablative conditioning, these authors found a cumulative incidence of 39% of Grade II to IV aGVHD in patients who did not receive any oral nutrition for nine or more days (13 patients). However, in 144 patients with oral intake, there was a cumulative incidence of only 7% of aGVHD. In the current study, all of the patients with gastrointestinal aGVHD required TPN and less than half of the patients without intestinal aGVHD required TPN, mainly for anorexia. However, due to the small number of patients with aGVHD no conclusions can be reached regarding the association between aGVHD and nutritional support. TPN has been associated with intestinal atrophy and enhanced expression of interferon gamma, while local levels of cytokines that protect from GVHD, such as IL-4 and IL-10, usually show a significant decrease in patients using this type of nutritional support.[@bib0365] Furthermore, many studies in critical patients have consistently shown a higher incidence of infectious complications in TPN versus oral/enteral nutrition, which may be another possible link between the feeding route and complications such as mucositis and aGVHD.[@bib0370]

In the current series, the majority of patients requiring nutritional support received TPN. Controversy exists on the best nutritional support after transplantation. A study by Szeluga et al.[@bib0375] showed that compared to oral nutrition, TPN was not associated with OS or hematopoietic recovery and length of hospitalization but was associated with a longer use of diuretics, more hyperglycemia and more catheter-related complications. Recent studies have suggested that early enteral support could be associated with better outcomes compared to TPN, including faster engraftment times.[@bib0380], [@bib0385] However up to 90% of the patients undergoing myeloablative allo-HSCT will still receive TPN.[@bib0390] In the current series, one-third of the auto-HSCT and two thirds of the allo-HSCT received TPN.

The main limitation of this study is its retrospective nature, which precludes the investigation of causative associations between variables and outcomes. However, this study identifies some variables that should be considered to predict the evolution of patients during the acute phases of HSCT, and to develop more precise ways to assess nutritional status.

Conclusions {#sec0070}
===========

This study shows that allo-HSCT and auto-HSCT patients become significantly hypercatabolic during the acute phase of transplants and the majority will develop mucositis requiring nutritional support early in the course of the transplant process. Of all the variables analyzed, albumin and TUN were associated with clinical outcomes. OS was not associated with any nutritional parameter.

Since this is not a comparative study, we cannot predict the outcome of patients without appropriate nutritional support. However due to the frequency and severity of mucositis and the degree of catabolism it seems reasonable to deliver appropriate nutritional support although the best source is still under study, with studies suggesting advantages of enteral nutrition over TPN.

Conflicts of interest {#sec0075}
=====================

The authors declare no conflicts of interest.

The authors gratefully acknowledge the help provided by the nurses and hematology fellows participating in the care of our patients.

![Distribution of mucositis according to grade and type of hematopoietic stem cell transplantation.\
auto: autologous hematopoietic stem cell transplantation; allo: allogeneic hematopoietic stem cell transplantation.](gr1){#fig0005}

![Type of nutritional support required.\
auto: autologous hematopoietic stem cell transplantation; allo: allogeneic hematopoietic stem cell transplantation; NS: nutritional supplements; TPN: total parenteral nutrition; EN: enteral nutrition.](gr2){#fig0010}

###### 

Patient characteristics.

  ------------------------------------------ --------------
  *Gender -- n (%)*                          
   Male                                      33 (66)
   Female                                    17 (34)
                                             
  *Median Age -- years (range)*              41 (17--67)
                                             
  *Diagnosis -- n (%)*                       
   Acute leukemia                            26 (52)
   Myelodysplastic syndrome                  1 (2)
   Lymphoma                                  7 (14)
   Myeloma                                   13 (26)
   Aplastic anemia                           3 (6)
                                             
  *Average length of stay -- days (range)*   32 (19--109)
                                             
  *Type of transplant -- n (%)*              
   *Autologous*                              18 (36)
   *Allogeneic*                              32 (64)
    Related                                  20 (63)
    Unrelated                                9 (28)
    Cord                                     3 (9)
                                             
  *Conditioning -- n (%)*                    
   Myeloablative                             42 (84)
   Reduced intensity                         8 (16)
  ------------------------------------------ --------------

###### 

Conditioning regimens.

  -------------------------------------------------------------------------------------------------------------------------------
  Myeloablative regimen   Type of HSCT   *n* (%)   Indication        Therapy        Dose                       Days before HSCT
  ----------------------- -------------- --------- ----------------- -------------- -------------------------- ------------------
  Cy/TBI                  allo           21 (42)   Acute leukemia    TBI\           1320 cGy total\            5--2\
                                                                     Cy             60 mg/kg                   7--6

  Mel 200                 auto           12 (24)   Myeloma           Melphalan      200 mg/m^2^                2

  BEC                     auto           4 (8)     Lymphoma          Carmustine\    300 mg/m^2^\               6\
                                                                     Etoposide\     200 mg/m^2^ twice a day\   6--4\
                                                                     \              60 mg/kg                   \
                                                                     Cy                                        6--3

  Cy/ATG/MP               allo           2 (4)     Aplastic anemia   Cy\            50 mg/kg\                  5--2\
                                                                     ATG\           2.5 mg/kg\                 4--1\
                                                                     MP             250 mg/m^2^ twice a day    4--1

  Flu/Cy/TBI              allo/cord      3 (6)     acute leukemia    Fludarabine\   25 mg/m2\                  8--6\
                                                                     Cy\            60 mg/kg\                  7--6\
                                                                     TBI            1320 cGy total             4--1
  -------------------------------------------------------------------------------------------------------------------------------

  ---------------------------------------------------------------------------------------------------------------------
  Reduced intensity regimens   Type of HSCT   *n* (%)   Indication       Therapy        Dose          Days before HCT
  ---------------------------- -------------- --------- ---------------- -------------- ------------- -----------------
  Flu/Mel                      allo           2 (4)     Lymphoma         Fludarabine\   30 mg/m^2^\   8--4\
                                                                         Melphalan      70 mg/m^2^    3--2

  Flu/Cy/TBI                   allo           5 (10)    Acute Leukemia   Fludarabine\   40 mg/m^2^\   6--2\
                                                                         Cy\            50 mg/kg\     6\
                                                                         TBI            200 cGy       1

  Mel 140                      auto           1 (2)     Myeloma          Melphalan      140 mg/m^2^   2
  ---------------------------------------------------------------------------------------------------------------------

HSCT: hematopoietic stem cell transplantation; allo: allogeneic; auto: autologous; TBI: total body irradiation; Cy: cyclophosphamide; ATG: anti-thymocyte globulin; MP: methylprednisolone.

###### 

Nutritional assessment comparing allogeneic and autologous hematopoietic stem cell transplantation at different time points.

  -----------------------------------------------------------------------------------
  Parameter                     Allo\                Auto\                *p*-Value
                                Mean (range)         Mean (range)         
  ----------------------------- -------------------- -------------------- -----------
  *At admission*                                                          

   BMI -- kg/m^2^               27.0 (22.7--31.3)    27.0 (23.8--30.2)    0.99

   DNM -- kg                    74.0 (48.1--99.9)    95.2 (66.9--123.5)   0.053

   Albumin -- mg/dL             4.12 (3.8--4.4)      4.12 (3.8--4.4)      0.99

   Prealbumin -- mg/dL          25.37 (19.8--30.9)   25.22 (18.9--31.5)   0.93

   TUN -- g/24 h                18.77 (9.9--27.5)    19.43 (13.2--25.6)   0.80

   TG -- mg/dL                  171 (68--274)        103 (28--152)        0.07

                                                                          

  *Ten days after transplant*                                             

   BMI -- kg/m^2^               19.04 (8.0--30.0)    15.33 (3.7--26.8)    0.27

   DNM -- kg                    72.09 (51.0--93.1)   70.85 (50.0--91.6)   0.89

   Albumin -- mg/dL             3.23 (2.2--3.9)      3.42 (2.9--3.9)      0.08

   Prealbumin -- mg/dL          17.74 (9.6--25.8)    19.99 (11.1--28.7)   0.29

   TUN -- g/24 h                21.63 (14.6--28.6)   22.96 (15.2--30.7)   0.56

   TG -- mg/dL                  263 (138--387)       111 (49--173)        0.014

                                                                          

  *Before discharge*                                                      

   BMI -- kg/m^2^               N/D                  N/D                  

   DNM -- kg                    N/D                  N/D                  

   Albumin -- mg/dL             3.43 (2.9--3.9)      3.53 (3.1--3.9)      0.52

   Prealbumin -- mg/dL          23.21 (13.7--32.6)   21.26 (15.6--26.8)   0.54

   TUN -- g/24 h                23.25 (12.9--33.5)   21.21 (14.5--27.9)   0.56

   TG -- mg/dL                  331 (148--514)       N/D                  
  -----------------------------------------------------------------------------------

Allo: allogeneic; Auto: autologous; BMI: body mass index; DNM: dynamometry; TUN: total Urinary Nitrogen; TG: triglycerides; N/D: no data available.

###### 

Nutritional assessment before transplant, 10 days after transplant and at discharge.

  -----------------------------------------------------------------------------------------------
  Parameter             Before transplant\   Day +10\             Before discharge\   *p*-Value
                        Mean (range)         Mean (range)         Mean (range)        
  --------------------- -------------------- -------------------- ------------------- -----------
  BMI (kg/m^2^)         26.9 (20.9--34.6)    26.1 (20.0--34.7)    N/D                 \<0.01

  DNM (kg)              79.7 (24.3--142.0)   72.5 (33.0--109.0)   N/D                 0.9

  Albumin (mg/dL)       4.1 (3.5--4.9)       3.3 (2.2--4.0)       3.5 (2.0--4.4)      \<0.01

  Pre-albumin (mg/dL)   25.4 (14.6--35.5)    18 (7.2--34.5)       21.9 (10.9--50.4)   \<0.01

  TUN g/24 h            18.2 (4.0--44.6)     22.1 (9.9--41.4)     22.6 (9.0--50.0)    0.1

  TG (mg/dL)            148.7 (40--465)      235 (46--557)        324.8 (96--863)     \<0.01
  -----------------------------------------------------------------------------------------------

BMI: body mass index; DNM: dynamometry; TUN: total urinary nitrogen; TG: triglycerides; N/D: no data available.

###### 

Nutritional assessment before and after hematopoietic stem cell transplantation according to the type of transplantation.

  Parameter              Before   Day +10   At discharge   *p*-Value
  ---------------------- -------- --------- -------------- -----------
  *Allogeneic*                                             
   BMI (kg/m^2^)         26.6     25.8      N/D            0.13
   DNM (kg)              76.1     74.5      N/D            0.85
   Albumin (mg/dL)       4.1      3.25      3.4            \<0.01
   Pre-albumin (mg/dL)   25.6     15.7      23.2           0.01
   TUN g/24 h            18.9     21.5      23.2           0.19
   TG (mg/dL)            172.5    255.5     331.8          \<0.05
                                                           
  *Autologous*                                             
   BMI (kg/m^2^)         27.3     26.3      N/D            \<0.05
   DNM (kg)              89.7     69        N/D            0.6
   Albumin (mg/dL)       4.16     3.4       3.5            \<0.01
   Pre-albumin (mg/dL)   25.2     20.5      21.2           0.054
   TUN g/24 h            17.2     23.9      21.2           0.39
   TG (mg/dL)            111      103       272.5          0.072

Results shown as means.

BMI: body mass index; DNM: dynamometry 85% standard for age and gender; TUN: total urinary nitrogen; TG: triglycerides; N/D: no data available.

###### 

Significance (*p*-values) by multivariate analysis of factors potentially associated with complications of hematopoietic stem cell transplantation.

  Factor                    HCT complications                                   
  ------------------------- ------------------- ------- ------- ------- ------- -------
  BMI before HSCT           0.444               0.277   0.326   0.25    0.249   0.925
  Albumin after HSCT        0.738               0.463   0.871   0.36    0.322   0.689
  Pre-albumin before HSCT   0.765               0.199   0.639   0.128   0.054   0.819
  TUN before HSCT           0.625               0.052   0.786   0.397   0.171   0.613
  BMI after HSCT            0.057               0.149   0.995   0.342   0.303   0.863
  Albumin after HSCT        0.152               0.012   0.835   0.271   0.015   0.822
  Pre-albumin after HSCT    0.507               0.062   0.797   0.167   0.065   0.391
  TUN after HSCT            0.945               0.13    0.503   0.087   0.026   0.932
  Days of TPN               0.834               0.001   0.062   0.002   0.001   0.159
  Albumin before d/c        0.295               0.125   0.653   0.161   0.193   0.358
  Pre-albumin before d/c    0.073               0.827   0.69    0.350   0.309   0.297
  TUN before d/c            0.165               0.304   0.084   0.029   0.344   0.556

aGVHD: acute graft versus host disease; LOS: length of hospital stay; IC: infectious complications; TNE: time to neutrophil engraftment; TPE: time to platelet engraftment; OS: overall survival; HSCT: hematopoietic stem cell transplantation; BMI: body Mass Index; TUN: total urinary nitrogen; TPN: total parenteral nutrition; d/c: discharge.
